Tag: adverse events

Introduction Bio-pharmaceutical companies have always had a responsibility to report adverse events (AE), whether in clinical development or post market-approval scenarios, to the Food and Drug Administration (FDA).  The COVID-19 pandemic and the race to find effective treatments for this disease has caused both the FDA and bio-pharmaceutical organizations around the world to re-imagine the […]